ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÐÂÎÅ
Group News
ASGCT 2024 | ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£ºµÍ¶¾¸ßЧµÄÐÂÒ»´ú»ùÒòдÈëϵͳӦÓÃÐÂÏ£Íû
2024-05-20

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

µ¼Óï

 

ÈÕǰ£¬£¬£¬£¬ £¬£¬ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¹ØÓڵͶ¾¸ßЧµÄÐÂÒ»´ú»ùÒòдÈëϵͳµÄ×îÐÂÑо¿Ï£ÍûÈëÑ¡2024ÄêµÚ27½ìÃÀ¹ú»ùÒòÓëÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÑ§»á£¨ASGCT£©Äê»á¡£¡£¡£ ¡£¡£¡£ASGCT½¨ÉèÓÚ1996Ä꣬£¬£¬£¬ £¬£¬ÊÇÈ«Çò×î´óµÄרҵ´ÓÊ»ùÒòºÍÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÑо¿µÄ·Ç׬ǮÐÔѧÊõ×éÖ¯¡£¡£¡£ ¡£¡£¡£ASGCTÄê»áÊÇÈ«Çò»ùÒòºÍÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁÆÁìÓò¹æÄ£×î´óµÄѧÊõ¾Û»á£¬£¬£¬£¬ £¬£¬ÎªÓë»áÕßÌṩÁËÒ»¸öÏÈÈÝ×îлùÒòÓëÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁƵĹú¼Êƽ̨¡£¡£¡£ ¡£¡£¡£ASGCT´ó»áÿÄêÎüÒýÈ«Çò¸÷µØÊýÒÔǧ¼ÆµÄѧÕß¡¢¿ÆÑ§¼Ò¡¢Ò½Éú¡¢FDA¹ÙÔ±¡¢¹¤Òµ½ç´ú±í¡¢Í¶×ÊÈ˼ÓÈë¡£¡£¡£ ¡£¡£¡£ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÍŽáÑïÖÝ´óѧ±¨µÀÁËÒ»ÖÖȫС¢ÓÐÓÃÇÒÇå¾²µÄ»ùÒòдÈëϵͳ--JL ת×ù×Óϵͳ£¬£¬£¬£¬ £¬£¬¸Ã JLת×ùøºÍÌ«ÖÊÁ£µÄJLת×ù×Óϵͳ¾ßÓиßת×ùЧÂʺ͵ÍDNAÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐÔÌØÕ÷£¬£¬£¬£¬ £¬£¬»ùÓÚJLת×ù×ÓÏµÍ³ÖÆ±¸µÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¾ßÓÐÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾»îÂʸߡ¢°©±äΣº¦µÍÒÔ¼°Ö×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾É±ÉË»îÁ¦Ç¿µÄÌØµã¡£¡£¡£ ¡£¡£¡£ÏÖÔÚÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Ê¹ÓøÃϵͳÕýÔÚ¿ªÕ¹30Сʱ¿ìËÙÐÍCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾Éú²ú¹¤ÒÕÑо¿¼°ÁÙ´²Ñо¿Ì½Ë÷¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͻ񻼁 - P737

 

ÕªÒªÎÊÌâ

 

The JL Transposon System: A Novel, Efficient, and Safe Tool for Gene and Cell Therapy with Lower Cytotoxicity and Enhanced Transposition Efficiency

 

ÕªÒªÄÚÈÝ

 

½«ÍâÔ´»ùÒò¸ßЧµÝËÍÖÁ°ÐÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾£¬£¬£¬£¬ £¬£¬¼á³Öºã¾ÃÎȹ̱í´ï£¬£¬£¬£¬ £¬£¬²¢¾¡¿ÉÄܵØïÔÌ­ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºÍ»ùÒò¶¾ÐÔÒ»Ö±ÊÇ»ùÒòÖÎÁÆÁìÓòÄÚËùÃæÁÙµÄÌôÕ½¡£¡£¡£ ¡£¡£¡£»£»£»£»£»£»£»£»ùÓÚDNAת×ù×ÓµÄÍâÔ´»ùÒòµÝËÍͬÑùÃæÁÙÉÏÊöÎÊÌ⣬£¬£¬£¬ £¬£¬ÐèÒª½øÒ»²½Ìá¸ßת×ùÕûºÏЧÂʺͽµµÍDNAʹÓüÁÁ¿´Ó¶ø½µµÍÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐÔ¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͼ 1 ¸ßЧÂʼ°¸ßÇå¾²ÐÔJLת×ùϵͳ¿ª·¢Õ½ÂÔ

 

ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÍŽáÑïÖÝ´óѧͨ¹ý´óÊý¾Ý»ùÒò×éÆÊÎö´ÓÈý¼¬Ó㣨Gasterosteus aculeatus£©»ùÒò×éÄÚ·¢Ã÷ÁËÐÂÐÍPSת×ù×Ó£¬£¬£¬£¬ £¬£¬½ÓÄɶ¨Ïò½ø»¯µÄ¶àÖÖÊÖÒÕÊֶλñµÃÁËÐÂÐ͸ßЧµÄJLת×ù×Óϵͳ£¬£¬£¬£¬ £¬£¬ÒÑʵÏÖÁ˱ÈÒ°ÉúÐÍPSת×ùø¸ßÊ®Óà±¶µÄЧÂÊÌáÉý¡£¡£¡£ ¡£¡£¡£Óë´Ëͬʱ£¬£¬£¬£¬ £¬£¬ÎÒÃÇ»¹¿ª·¢ÁËÎÞ¿¹ÉúËØÌ«ÖÊÁ£DNA£¨Tiniplasmid£©Éú²úϵͳ£¬£¬£¬£¬ £¬£¬Í¨¹ý×îС»¯¹Ç¼ÜDNA£¬£¬£¬£¬ £¬£¬Ôö½øÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºËתµ¼Ð§ÂÊ£¬£¬£¬£¬ £¬£¬½øÒ»²½Ìá¸ßÁËJL»ùÒòдÈëϵͳÕûÌåЧÄÜ¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͼ 2 ¹¤³Ì»¯¸ßЧPS ת×ùø¡£¡£¡£ ¡£¡£¡£A. SWISS-MODEL ͨ¹ý×Ô¶¯Í¬Ô´½¨Ä£ÊÖÒÕÌìÉú PS ת×ùø¶þ¾ÛÌåÀíÂÛÄ£×Ó£»£»£»£»£»£»£»£»B. ¹¤³Ì¸ßЧPS ת×ùø£¨ÒÔ JL ת×ùøΪÀý£©½á¹¹Óò×é֯ʾÒâͼ£»£»£»£»£»£»£»£»C. ÆÀ¹À²î±ð¹¤³Ì»¯ PS/JL ת×ùø±äÌåÔÚ CHO ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÐת×ùЧÂÊÌá¸ß¡£¡£¡£ ¡£¡£¡£

 

ΪÁ˸üºÃÆÀ¹ÀJL»ùÒòдÈëϵͳÔÚGCTÁìÓòµÄÓ¦ÓÃDZÁ¦£¬£¬£¬£¬ £¬£¬ÔÚ±¾´ÎASGCTµÄPosterÎÄÕÂÖУ¬£¬£¬£¬ £¬£¬ÎÒÃǶԻùÓÚJLת×ù×Ó¾ÙÐÐCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÆÔìµÄÉúÎïÑ§ÌØÕ÷¾ÙÐÐÁËÖÜÈ«ÆÀ¼Û¡£¡£¡£ ¡£¡£¡£Ñо¿Ð§¹ûÅú×¢£¬£¬£¬£¬ £¬£¬JL ת×ù×ÓϵͳÔÚÒ»ÂÉÌõ¼þÏÂ±È PiggyBac (PB) ºÍ˯ÓÈÎï (SB) µÈ¾­µäϵͳ¾ßÓиü¸ßЧµÄת×ùЧÂÊ£¬£¬£¬£¬ £¬£¬Í¬Ê±»¹¿ÉʵÏÖµÍÖÊÁ£¼ÁÁ¿ºÍµÍTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐÔ£¬£¬£¬£¬ £¬£¬¸ßCAR-T ÔöÖ³»îÐÔ¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

ͼ 3 ÒÔת×ùø mRNA ºÍת×ù×Ó Tiniplasmid® ÖÆ±¸CAR-TµÄÓÅÊÆ¡£¡£¡£ ¡£¡£¡£A. Tiniplasmid µÄʾÒâͼ£»£»£»£»£»£»£»£»B-C. Óë±ê×¼ÖÊÁ£ºÍ PB ת×ùø mRNA Ïà±È£¬£¬£¬£¬ £¬£¬Tiniplasmid ºÍ JL ת×ùø mRNA ¾ßÓиü¸ßµÄת×ùЧÂÊ¡¢¸üµÍµÄÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐԺ͸ü¿ìµÄÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÔöÖ³ÌØÕ÷¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͼ 4 »ùÓÚ MSLN CAR µÄ JL ת×ù×ÓϵͳµÄÌåÍâÆÀ¹À¡£¡£¡£ ¡£¡£¡£A. MSLN CAR-T µÄÖÆ±¸ºÍ¼ì²âÁ÷³Ìͼ£»£»£»£»£»£»£»£»B. µÚ 9 Ìì CAR+ ±í´ïµÄTÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾×ª×ùЧÂÊÆÀ¼Ûͼ£»£»£»£»£»£»£»£»C. RTCA ¼ì²âÏÔʾ MSLN CAR-T ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÓëÖ×Áö°ÐÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÒÔ 1:2 µÄ E:T ±ÈÀý¹²×÷Óý 24/48/72 СʱºóµÄ MSLN ÌØÒìÐÔÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐÔ¡£¡£¡£ ¡£¡£¡£NTΪ±ÈÕÕ£¨n=7£©¡£¡£¡£ ¡£¡£¡£

 

ΪÁËÑо¿Ç±ÔÚµÄÒÅ´«¶¾ÐÔ£¬£¬£¬£¬ £¬£¬ÎÒÃÇʹÓÃÓ«¹âËØÃ¸²â¶¨½ÏÁ¿ÁË JL ºÍ¹Å°åת×ù×Óϵͳ֮¼äµÄ×îºó·´ÏòÖØ¸´ (TIR) ·ÇÌØÒìÐÔÆô¶¯×Ó»îÐÔ¡£¡£¡£ ¡£¡£¡£Ð§¹ûÅú×¢£¬£¬£¬£¬ £¬£¬JLϵͳµÄ28bp TIRΪÏÖÔÚ·¢Ã÷µÄ×î¶Ìת×ù×ÓTIRÐòÁУ¬£¬£¬£¬ £¬£¬¾ßÓÐ×îµÍµÄ·ÇÌØÒìÐÔÆô¶¯×Ó»îÐÔ£¬£¬£¬£¬ £¬£¬¶ÔÄÚÔ´ÐÔ»ùÒò×ÌÈÅ×îС¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͼ 5 ³¬¶ÌÐÍTIR ¼°Æä·ÇÌØÒìÐÔÆô¶¯×Ó»îÐÔ¡£¡£¡£ ¡£¡£¡£A. ÔÚÆÕ±éÓ¦ÓÃÓÚ GCT µÄת×ù×ÓÖУ¬£¬£¬£¬ £¬£¬JL ת×ù× 28 bp TIR ÐòÁÐÊÇ×î¶ÌµÄ£¬£¬£¬£¬ £¬£¬ÕâºÜÊÇÓÐÀûÓÚ¼õСת×ù×ÓÖÊÁ£µÄ¾Þϸ£¡£¡£ ¡£¡£¡£¬£¬£¬£¬ £¬£¬´Ó¶øÌá¸ßת×ùЧÂÊ£»£»£»£»£»£»£»£»B. ±ðµÄ£¬£¬£¬£¬ £¬£¬ÓëÆäËûת×ù×ÓÏà±È£¬£¬£¬£¬ £¬£¬JL ת×ù× TIR Ïà¹Ø·ÇÌØÒìÐÔÆô¶¯×Ó»îÐÔ×îµÍ¡£¡£¡£ ¡£¡£¡£SB£ºË¯ÓÈÎïת×ù×Ó TIR£¬£¬£¬£¬ £¬£¬PB£ºPiggyBacת×ù×ÓTIR£¬£¬£¬£¬ £¬£¬JL-PS£ºPasserת×ù×ÓTIR¡£¡£¡£ ¡£¡£¡£

 

±ðµÄ£¬£¬£¬£¬ £¬£¬ÎÒÃÇʹÓÃÅþÁ¬×ӽ鵼µÄ°Ð±êÀ©Ôö PCR (LTA-PCR)¡¢¶þ´ú²âÐòºÍÉúÎïÐÅϢѧ¹¤¾ß¾ÙÐÐÁËÈ«»ùÒò×éÕûºÏλµãÆÊÎö (ISA)£¬£¬£¬£¬ £¬£¬ÒÔÆÊÎö JL ת×ù×ÓµÄÕûºÏλµãÌØÕ÷¡£¡£¡£ ¡£¡£¡£Ð§¹ûÅú×¢£¬£¬£¬£¬ £¬£¬675 ¸öÆæÒìµÄÕûºÏλµãËæ»úÂþÑÜÔÚÕû¸ö»ùÒò×éÖУ¬£¬£¬£¬ £¬£¬IS ûÓÐÔÚת¼Æðʼλµã (TSS)ÖÜΧµÄÆ«ºÃÐÔ¡£¡£¡£ ¡£¡£¡£Æ½¾ù¶øÑÔ£¬£¬£¬£¬ £¬£¬69.14% µÄÆæÒìÕûºÏλµã (UIS) ±¬·¢ÔÚ»ùÒòÄÚ£¨79.67% ÔÚ»ùÒò ± 10 kb ÄÚ£©£¬£¬£¬£¬ £¬£¬ÆäÖоø´ó´ó¶¼²åÈëλµãÔÚÄÚº¬×ÓÇø¡£¡£¡£ ¡£¡£¡£ËùÓÐÓë°©Ö¢Ïà¹Ø»ùÒòÏà¹ØµÄλµãµÄÏà¶Ô¼ÆÊý±ÈµÍÓÚ0.5%£¬£¬£¬£¬ £¬£¬²¢ÇÒÔÚÕûºÏλµãÄÚûÓз¢Ã÷ÓëÒÑÖªµÄÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ºÍ»ùÒòÖÎÁƲ»Á¼ÊÂÎñÏà¹ØµÄ»ùÒò¡£¡£¡£ ¡£¡£¡£±ðµÄ£¬£¬£¬£¬ £¬£¬´ÓÉÏÊö²åÈëλµãÆÊÎöЧ¹ûÀ´¿´£¬£¬£¬£¬ £¬£¬Ã»Óз¢Ã÷ÕûºÏȺ¼¯ÐÔÈÈÃÅ¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

ͼ 6 ʹÓÃÅþÁ¬°Ð±êÀ©Ôö PCR£¨LTA-PCR£©»æÖÆµÄ JL ת×ù×ÓÕûºÏͼÆ×ºÍ UISs µÄÈ«»ùÒò×éͼÆ×¡£¡£¡£ ¡£¡£¡£A. Ñù±¾Öмì²âµ½µÄÊ®¸ö´ú±íÐÔ×îÇ¿µÄ UISs µÄÀÛ»ýƵÂÊ£»£»£»£»£»£»£»£»B. ¶à¿Ë¡-µ¥¿Ë¡¾àÀ루PMD£©ÆÊÎö¡£¡£¡£ ¡£¡£¡£¿£¿£¿ £¿£¿ £¿£¿£¿Ë¡¶àÑùÐÔÆ¾Ö¤À×ÄáìØ¾ÙÐÐÆÀ¹À£¬£¬£¬£¬ £¬£¬PMD ÆÊÎö»ùÓÚÁ½¸öÒòËØ£ºÔȳƶȺ͸»ºñ¶È¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

C. ÔØÌåÕûºÏÔÚȾɫÌåÖеÄÂþÑÜ£»£»£»£»£»£»£»£»D. ÔØÌåÕûºÏÔÚת¼ÆðʼλµãÖÜΧµÄÂþÑÜ¡£¡£¡£ ¡£¡£¡£¹èѧ£ºÅÌËã»úÄ£ÄâµÄËæ»úÕûºÏ²Î¿¼¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

 

E-F. ÔØÌåÕûºÏÔÚ»ùÒòÇøµÄÂþÑÜ¡£¡£¡£ ¡£¡£¡£E£º»ùÒòÄÚ»ò»ùÒòÄÚ ±10 kb¡£¡£¡£ ¡£¡£¡£F£ºÔÚÍâÏÔ×Ó»òÄÚº¬×ÓÖС£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾

G. °©Ö¢Ïà¹Ø»ùÒò TSS ÉÏÏÂÓÎ 100 kb ¹æÄ£ÄÚ IS µÄÏà¶ÔТ˳£»£»£»£»£»£»£»£»H. ËùÓмì²âµ½µÄÅäºÏÕûºÏλµãÖ±¹ÛÏÔʾµÄÔØÌåÕûºÏÈÈÃÅÂþÑÜ¡£¡£¡£ ¡£¡£¡£Ã¿¸öÀ¶É«Ô²È¦´ú±íÒ»¸öµã£»£»£»£»£»£»£»£»ºìÉ«ÎÄ×ÖÏÔʾÕûºÏÈÈÃÅ»ùÒòÃû³Æ¡£¡£¡£ ¡£¡£¡£

 

½áÂÛ£º

1. »ùÓÚÍ¬Ô´ÊØ¾ÉÐԵİëÀíÐÔÉè¼ÆPS ת×ùøͻ±äÌ壬£¬£¬£¬ £¬£¬ºÍÁÁ°±ËáÀ­Á´ÈÚºÏÂѰ×Õ½ÂÔ£¬£¬£¬£¬ £¬£¬ÎÒÃÇ»ñµÃÁËÒ»¸ö¹¤³Ì»¯¸ßЧJL ת×ùøºÍת×ù×Óϵͳ¡£¡£¡£ ¡£¡£¡£

2. »ùÓÚ¹¤³Ì»¯¸ßЧJLת×ùømRNAºÍÌ«ÖÊÁ£µÄת×ù×Óϵͳ¾ßÓиßת×ùЧÂʺ͵ÍDNAÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¶¾ÐÔÌØÕ÷¡£¡£¡£ ¡£¡£¡£

3. »ùÓÚJLת×ùÃ¸ÏµÍ³ÖÆ±¸µÄCAR-TÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¾ßÓкÜÇ¿µÄɱÉËÖ×ÁöÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾µÄÄÜÁ¦¡£¡£¡£ ¡£¡£¡£

4. »ùÓÚJLת×ùÃ¸ÏµÍ³ÖÆ±¸µÄCAR-T ÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾¾ßÓеͻùÒò¶¾ÐԺ͸ßÇå¾²ÐÔ¡£¡£¡£ ¡£¡£¡£

ÕâЩÑо¿Åú×¢£¬£¬£¬£¬ £¬£¬JL ת×ù×ÓϵͳÊÇ»ùÒòºÍÓÅÓιú¼Ê¡¤UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾ÖÎÁƵÄÒ»ÖÖȫС¢ÓÐÓÃÇÒÇå¾²µÄÐÂÐ͵ÝËÍÒªÁ죬£¬£¬£¬ £¬£¬²¢ÇÒÊÇδÀ´Ñо¿ºÍÁÙ´²Ó¦ÓõÄÓÐǰ;µÄ¹¤¾ß¡£¡£¡£ ¡£¡£¡£

 

UB8(ÖйúÓÎ)¼¯ÍŹٷ½ÍøÕ¾
·µ»Ø¶¥²¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿